What it is: A modified fragment of human growth hormone engineered specifically to trigger fat breakdown without the growth-promoting or insulin-affecting properties of full GH.
Research suggests: Preclinical studies showed strong selective fat reduction; Phase 2 human trials were completed and a partial safety record was established.
Best for: Body composition and fat loss researchers
Key thing to know: Received GRAS (Generally Recognized As Safe) status in the US as a food additive, which provides a limited but real human safety reference.
What is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a modified peptide fragment corresponding to amino acids 177–191 of the C-terminal region of human growth hormone, with an additional tyrosine residue at the N-terminus to improve stability. It was developed by researchers at Monash University in Australia with a specific design objective: isolate the lipolytic (fat-burning) properties of growth hormone while eliminating its growth-promoting effects and metabolic side effects , particularly IGF-1 elevation and insulin resistance.
AOD-9604 advanced through Phase 1 and Phase 2 clinical trials for the treatment of obesity, making it one of the more formally studied compounds in this category. Commercial development was ultimately discontinued not due to safety concerns, but because Phase 2 fat loss results did not reach the efficacy threshold required to advance to Phase 3 for the obesity indication. More recent research interest has shifted toward its potential role in cartilage repair and regeneration, where early in vitro and animal data have generated independent scientific attention.
How it works.
Full-length human growth hormone stimulates fat breakdown (lipolysis) through beta-3 adrenergic receptor activation, but it simultaneously elevates IGF-1 and can impair insulin sensitivity , effects that complicate its use as a metabolic therapeutic. AOD-9604 was specifically engineered to retain the lipolytic activity of the hGH C-terminal fragment while decoupling it from the growth-promoting and insulin-disrupting pathways.
Research suggests AOD-9604 stimulates lipolysis , the release of stored triglycerides from fat cells for use as fuel , and inhibits lipogenesis (the formation of new fat) through the beta-3 adrenergic pathway, without activating IGF-1 receptors or insulin signaling. Think of it as extracting one specific tool from the growth hormone toolkit , the fat-metabolism function , and using it in isolation without the broader hormonal effects that make full GH protocols more complex to manage.
The cartilage repair research involves a separate observation: AOD-9604 appears to influence proteoglycan synthesis in chondrocytes (cartilage cells), with in vitro data suggesting it may support cartilage matrix maintenance. This mechanism is distinct from its lipolytic activity and represents an emerging area of research independent of the original obesity indication.
What the research shows.
AOD-9604 completed Phase 1 trials confirming human safety and tolerability, with no significant adverse events and confirmed absence of IGF-1 elevation , validating the design premise. Phase 2 trials enrolled obese subjects over 12–24 weeks and demonstrated modest fat loss compared to placebo, alongside favorable safety data. However, the fat loss effect size did not reach the threshold required by regulators for the obesity indication, and commercial development was discontinued.
The Phase 2 human data represents a meaningful but qualified evidence base: the compound was tested in humans, was safe and tolerable, and did produce some fat loss , but the magnitude of effect was insufficient for its intended regulatory purpose. Extrapolating from these results requires acknowledging that the primary clinical endpoint was not met at the doses studied.
Cartilage repair research is at an earlier stage , primarily in vitro and preclinical studies , with no Phase 2 human data yet published for this indication. This emerging research line is scientifically interesting but should be treated as hypothesis-generating rather than clinically established.
Biomarkers to review first.
Metabolic baseline markers are most relevant to the contexts in which AOD-9604 is researched. IGF-1 is included as a monitoring marker to confirm the absence of IGF-1 elevation , a key design feature of this compound.
What it's commonly researched with.
AOD-9604 is most often discussed in the context of metabolic and body composition protocols, sometimes alongside GH secretagogues or GLP-1 receptor agonists that target complementary fat loss pathways. These pairings represent what appears in the research and community literature , not recommendations for use.